WO2004004757A1 - Treatment for eye disorder - Google Patents
Treatment for eye disorder Download PDFInfo
- Publication number
- WO2004004757A1 WO2004004757A1 PCT/US2003/020672 US0320672W WO2004004757A1 WO 2004004757 A1 WO2004004757 A1 WO 2004004757A1 US 0320672 W US0320672 W US 0320672W WO 2004004757 A1 WO2004004757 A1 WO 2004004757A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- molecule
- bruch
- diffusion
- tissue
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title claims abstract description 35
- 238000011282 treatment Methods 0.000 title abstract description 24
- 210000001775 bruch membrane Anatomy 0.000 claims abstract description 140
- 210000001519 tissue Anatomy 0.000 claims abstract description 76
- 239000012528 membrane Substances 0.000 claims abstract description 43
- 210000004379 membrane Anatomy 0.000 claims abstract description 39
- 238000009792 diffusion process Methods 0.000 claims abstract description 34
- 230000003213 activating effect Effects 0.000 claims abstract description 26
- 238000002604 ultrasonography Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 98
- 208000002780 macular degeneration Diseases 0.000 claims description 54
- 235000018102 proteins Nutrition 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 40
- -1 o-nitrobenzyl Chemical group 0.000 claims description 40
- 102000004190 Enzymes Human genes 0.000 claims description 35
- 108090000790 Enzymes Proteins 0.000 claims description 35
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 29
- 238000012014 optical coherence tomography Methods 0.000 claims description 29
- 230000004913 activation Effects 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 22
- 230000004075 alteration Effects 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000007850 fluorescent dye Substances 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 10
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 claims description 10
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 10
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 9
- 239000003599 detergent Substances 0.000 claims description 9
- 239000002502 liposome Substances 0.000 claims description 9
- IRFHMTUHTBSEBK-QGZVFWFLSA-N tert-butyl n-[(2s)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC(C)(C)C)=CC(F)=CC=C1F IRFHMTUHTBSEBK-QGZVFWFLSA-N 0.000 claims description 9
- 230000004382 visual function Effects 0.000 claims description 8
- 238000012800 visualization Methods 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- 239000002961 echo contrast media Substances 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 208000027073 Stargardt disease Diseases 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 230000000593 degrading effect Effects 0.000 claims description 6
- 239000000975 dye Substances 0.000 claims description 6
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 claims description 6
- 108090001060 Lipase Proteins 0.000 claims description 5
- 102000004882 Lipase Human genes 0.000 claims description 5
- 239000004367 Lipase Substances 0.000 claims description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 5
- 108010055297 Sterol Esterase Proteins 0.000 claims description 5
- 102000000019 Sterol Esterase Human genes 0.000 claims description 5
- 235000019421 lipase Nutrition 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- 201000006321 fundus dystrophy Diseases 0.000 claims description 4
- 229930195712 glutamate Natural products 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 3
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 102000005600 Cathepsins Human genes 0.000 claims description 2
- 108010084457 Cathepsins Proteins 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 abstract description 26
- 238000006731 degradation reaction Methods 0.000 abstract description 24
- 239000000126 substance Substances 0.000 abstract description 20
- 210000001525 retina Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 9
- 210000003161 choroid Anatomy 0.000 abstract description 2
- 230000003413 degradative effect Effects 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 12
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 10
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 10
- 206010025421 Macule Diseases 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000004393 visual impairment Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 8
- 230000008719 thickening Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000004569 Blindness Diseases 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 230000002186 photoactivation Effects 0.000 description 5
- 238000002428 photodynamic therapy Methods 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 4
- 208000022873 Ocular disease Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 108091008695 photoreceptors Proteins 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000004300 dark adaptation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005043 peripheral vision Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000004911 serous fluid Anatomy 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001585 trabecular meshwork Anatomy 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- HXBMIQJOSHZCFX-UHFFFAOYSA-N 1-(bromomethyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1CBr HXBMIQJOSHZCFX-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical compound [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012713 reactive precursor Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- the present invention is generally directed to the fields of ophthalmology and cell biology. Specifically, it relates to altering the physical and/or chemical properties of an ocular tissue. More specifically, it describes a means to detect and/or reduce the thickening and/or change the permeability of Bruch' s membrane associated with eye disorders, such as macular degeneration. Even more specifically, it regards administration of an inactivated diffusion-enhancing molecule to Bruch' s membrane followed by activation of the diffusion- enliacing molecule through an energy source.
- AMD Age related macular degeneration
- Macular degeneration is categorized as either dry (atrophic) or wet (neovascular).
- the dry form is more common than the wet, with about 90% of AMD patients diagnosed with dry AMD.
- the wet form of the disease usually leads to more serious vision loss.
- RPE retinal pigment epithelial cells
- atrophic AMD The clinical hallmark of atrophic AMD is accumulation of macular drusen, yellowish deposits just deep to the retinal pigment epithelium ("RPE"). Histopathologic examination of eyes with atrophic AMD reveals deposition of lipid and proteinaceous material deep to the RPE in Bruch' s membrane. In aged eyes with AMD, Bruch' s membrane is often about 3 times thicker than normal.
- This thickening is thought to be comprised of lipid as well as modified and cross-linked protein, which impedes transport of nutrients across Bruch' s membrane from the choriocapillaris to the outer retina
- This thickened barrier comprised of lipid and cross-linked protein impedes transport of nutrients across Bruch' s membrane from the choriocapillaris to the outer retina.
- ARMD may be caused by chronic exposure of the retina to light.
- AMD is a challenging disease for both patient and doctor, because there are very few treatment options and, with the exception of anti-oxidants, no proven preventative therapy. While some individuals experience only minor inconvenience from macular degeneration, many others with more severe forms of macular degeneration are incapacitated. Current therapies, including laser photocoagulation, photodynamic therapy, and anti-angiogenic therapeutics have had mixed results, and, in certain instances, have caused deleterious side effects. A need therefore exists for a treatment that reduces or limits the effects of macular degeneration.
- the compound Shortly after administration, the compound is activated with a pre-calculated dose of light at a particular wavelength, resulting in conversion of normal oxygen to free radical singlet oxygen, which in turn causes closure of neovascular tissue.
- the therapy in specific embodiments, treats the blood vessel proliferation.
- choroidal neovascularization with photodynamic therapy, recurrent neovascularization occurs commonly within several months after treatment.
- U.S. Patent No. 5,756,541 is directed to methods to improve visual acuity including administering a photoactive compound in an amount sufficient to localize to a target ocular tissue and irradiating the target tissue with light from a laser, wherein the wavelength of radiation is absorbed by the photoactive compound and the radiation is conducted for a time and at an intensity sufficient to improve visual acuity.
- the photoactive compound is a green porphyrin.
- U.S. Patent No. 5,910,510 is directed to an identical method having a particular irradiation timing.
- U.S. Patent No. 5,798,349 regards methods to treat conditions of the eye characterized by unwanted neovascularure, such as AMD, by administering a liposomal formulation of a green porphyrin in an amount and time sufficient to localize in the neovascularure, followed by irradiation of the neovasculature with laser light, wherein the light absorbed by the green porphyrin occludes the neovasculature.
- the irradiance is in a range from about 300 mW/cm 2 to about 900 mW/cm 2 .
- U.S. Patent No. 6,128,525 is directed to method and apparatus controlling dosimetry of photodynamic therapy.
- U.S. Patent No. 5,935,942 regards methods of occluding vasculature in a mammalian eye including co-administering intravenously a fluorescent dye encapsulated with heat-sensitive liposomes and a tissue-reactive agent activated by irradiation.
- the liposomes are heated in the eye to release their contents, wherein the tissue-reactive agent remains inactive, followed by monitoring of fluorescent dye flow within the vasculature.
- the tissue-reactive agent is activated in the vasculature having subnormal blood flow, such that the activated agent chemically occludes the vasculature.
- 6,140,314 methods further comprise coadministration of a tissue-specific factor effective to impair growth or regeneration of a blood vessel.
- the related U.S. 6,248,727 regards related diagnostic reagents and kits.
- the present invention regards methods and compositions for altering physical and/or chemical properties of an ocular tissue, hi specific embodiments, it refers to enhancement of diffusion through or across a tissue, targeted destruction of cells, and/or targeted alteration of at least part of at least one ocular tissue in an individual. This may be accomplished, in particular embodiments, using a means to effect a controlled enhancement of diffusion and/or other controlled alteration, such as with light or ultrasound. Some aspects of the present invention are directed to treating eye disorders at early stages, and a skilled artisan will recognize the utility of this invention for such a purpose.
- Bruch' s membrane is the targeted tissue. With aging and especially in macular degeneration, Bruch' s membrane develops a lipid and cross-linked protein barrier. Impaired diffusion across Bruch' s membrane in patients with macular degeneration, promotes release of angiogenic factors by the nutritionally deprived retina. This, in turn, causes growth of neovascular tissue through Bruch' s membrane with subsequent bleeding, leakage of serous fluid, and severe visual loss. Some aspects of the present invention allow treatment/administration before or shortly after choroidal neovascularization develops.
- the tissue-altering molecule is administered in inactive form, such as by systemic injection or ingestion, or local (intraocular, periocular) injection, hi a specific embodiment, the molecule is lipophilic. It binds to multiple tissues in an inactive form before it is gradually eliminated. It is only activated by an energy source ⁇ e.g. light, ultrasound, or both) that is precisely applied to the eye to achieve preferential activation of the tissue-altering substance in Bruch' s membrane.
- an energy source e.g. light, ultrasound, or both
- the tissue-altering molecules alter the lipids and/or cross-linked protein in Bruch' s membrane, such as to improve transmembrane diffusion.
- the photochemical activation steps comprise 2-photon photo-chemistry.
- an eye disorder comprising the step of increasing diffusion across Bruch's membrane in said eye.
- the increased diffusion is a result of reducing the thickness, altering the composition, or both, of said membrane.
- a method for increasing diffusion across Bruch's membrane in at least one eye of an individual comprising the steps of administering to the Bruch's membrane an inactive form of a degradation molecule in an amount sufficient to form a Bruch's membrane/inactive degradation molecule complex; and exposing said complex to an activating source, wherein said activating source activates said inactive degradation molecule into an active form of said degradation molecule, said activation resulting in an increase in diffusion across said membrane.
- the increase in diffusion is a result of reducing the thickness or altering the composition of said membrane.
- the increase in diffusion is a result of alteration of a lipid, a cross-linked protein, or both in the membrane.
- the individual has an eye disorder, such as AMD, juvenile macular degeneration, Sorby's fundus dystrophy, or age-related decrease in visual function unrelated to macular degeneration, h a specific embodiment, the inactive degradation molecule binds directly to the membrane.
- the inactive degradation molecule is a protein, detergent, surfactant (useful for caged cyclodextrin).
- the protein is an enzyme.
- the inactive enzyme is further defined as being caged by the incorporation of at least one photo- removable protecting group on an amino acid sidechain of said enzyme.
- the protecting group is o-nitrobenzyl, desyl, phenacyl, trans-o-cinnamoyl, coumarinyl, quinoline-2-only, xanthenyl, thioxanthenyl, selenoxanthenyl and anthracenyl, stilbenyl, or a combination thereof
- the protecting group is o- nitrobenzyl, desyl, phenacyl, trans-o-cinnamoyl, coumarinyl, quinoline-2-only, xanthenyl, thioxanthenyl, selenoxanthenyl and anthracenyl, stilbenyl or derivatives thereof
- the amino acid is cysteine, aspartate, glutamate, histidine, lysine, asparagine, glutamine, arginine, serine, threonine, tyrosine, or a combination thereof
- the protein is further defined as being caged in an ultrasound contrast agent.
- the ultrasound contrast agent is a microbubble or a liposome.
- the protein further comprises a protein binding domain.
- the protein binding domain is a heterodimeric domain.
- the protein binding domain is a leucine zipper domain, a chitin-binding domain, or a Src homology 2 (SH2) domain.
- the inactive degradation molecule is administered to the individual in a pharmacologically acceptable composition.
- the inactive degradation molecule is administered in a pharmacologically acceptable composition systemically to the individual.
- the inactive degradation molecule is administered in a pharmacologically acceptable composition to the individual orally, by injection (such as periocular or intraocular), rectally, vaginally, or topically.
- the enzyme is a matrix metalloproteinase, a cholesterol esterase, a lipase, a cathepsin, a protease, or a combination thereof.
- tissue-altering agent refers to at least one molecule that changes the physical, chemical, or both properties of a tissue.
- the term refers to an agent that alters a tissue such that diffusion through or across is improved, at least partially.
- the term refers to an agent that is capable of at least (that at least in part is undesirable) partially degrading components of a tissue.
- the term refers to an agent that is capable of reducing lipids and/or cross-linked proteins in a tissue, such as Bruch's membrane.
- the term regards degrading one or more of its components.
- the tissue-altering molecule is a detergent that can extract lipidic and non-lipidic deposits from within a tissue such as Bruch's membrane.
- ultrasound contrast agent refers to microstructures that can carry exogenous contrast agents. These microstructures can be disrupted by focused application of ultrasound irradiation. Examples include microbubbles (tiny gas bubbles, in suspension, that can strongly scatter ultrasound) or liposomes.
- the present invention is directed to the treatment of an eye disorder, particularly by effecting alteration of ocular tissue related to the disorder.
- This alteration may be of any kind, so long as the tissue is altered, but in particular embodiments it refers to enhancement of diffusion of a tissue using methods and compositions described herein.
- the methods and compositions affect Bruch's membrane to improve an ocular disorder.
- the present invention is directed to the treatment of glaucoma with topical administration of at least one tissue-altering agent.
- Such treatment is useful for glaucoma, such as for the particular embodiment of alleviating a clogged trabecular meshwork in the pathogenesis of glaucoma.
- the present invention regards treatment for macular degeneration, either dry or wet.
- wet AMD may be treated with the methods of the present invention, given that after treatment of wet macular degeneration by currently known methods, the condition commonly recurs (recurrent choroidal neovascularization).
- the therapy described herein prevents such recurrences and may limit the extent (growth) of existing choroidal neovascularization, thus maintaining better vision.
- the treatment by increasing nutritional delivery to the retina, the treatment causes regression of existing choroidal neovascularization.
- the present invention aims to treat eye disorders, such as macular degeneration, by focusing on the thickened Bruch's membrane associated with many eye disorders.
- This thickening is the result of abnormal deposition of lipid and cross-linked protein and precedes neovascularization through Bruch's membrane, followed by subsequent bleeding, leakage of serous fluid, and severe visual loss.
- an improvement in diffusion across Bruch's membrane is achieved, thereby reducing the lipid and cross-linked protein barrier that accumulates in individuals with eye disorders, to prevent development of visual loss.
- the chemical composition of the membrane is altered. For example, a detergent washes away lipids in the membrane. An enzyme degrades proteins within the membrane.
- the methods of the present invention result in an increase in hydraulic conductivity across Bruch's membrane and/or an increase in macromolecular and/or oxygen permeability of Bruch's membrane.
- an individual with signs or symptoms of an aging Bruch's membrane is administered, such as systemically or locally, an inactive tissue-altering molecule.
- the inactive molecules are visualizable prior to activation, such as by being fluorescent. Following sufficient time for adequate distrubution of the inactive molecules, the molecules accumulate within multiple tissues, including Bruch's membrane. Once sufficient amounts are reached at Bruch's membrane, the visualizability of the molecules is used to precisely target Bruch's membrane with an energy source, such as light or ultrasound, that activates the tissue-altering molecules selectively.
- the present invention is useful for visualization of Bruch's membrane, such as for diagnostic techniques. That is, an inactive fluorescent compound is administered to an individual and associates with Bruch's membrane, such as by binding a lipid in Bruch's membrane. Energy, such as in the form of light, or more specifically 2 photon irradiation, is focused on the complex of inactive photoactive compound/Bruch's membrane, and the inactive photoactive compound is then activated. Energy emitted from the photoactive compound, such as light, allows visualization of Bruch's membrane. In specific embodiments, the amount of light emitted is proportional to the amount of lipid in Bruch's membrane.
- the present invention utilizes a tissue-altering molecule for delivery to an ocular tissue, in specific embodiments for treatment in the eye.
- the tissue-altering molecule may be diffusion-enhancing, degradative, or both, and it preferably alters the physical, chemical, or both properties of the tissue.
- a diffusion-enhancing molecule acts to increase diffusion across Bruch's membrane by either a) reducing the thickness of the membrane itself; and/or b) reducing the amount of deposits within Bruch's membrane, and/or by changing the chemical nature of Bruch's membrane.
- the tissue-altering molecule is caged, hi other specific embodiments, the tissue-altering molecule is a degradative enzyme, such as cholesterol esterases, lipases, matrix metalloproteinases, or any enzyme, or protein in particular, such as that can increase diffusion across Bruch's membrane, preferably by degrading one or more of its components, hi other specific embodiments, the tissue-altering molecule is a detergent that can extract lipidic and non-lipidic deposits from within Bruch's membrane, which will increase diffusion across Bruch's membrane.
- a degradative enzyme such as cholesterol esterases, lipases, matrix metalloproteinases, or any enzyme, or protein in particular, such as that can increase diffusion across Bruch's membrane, preferably by degrading one or more of its components
- the tissue-altering molecule is a detergent that can extract lipidic and non-lipidic deposits from within Bruch's membrane, which will increase diffusion across Bruch's membrane.
- the tissue-altering molecule is formulated so as to provide an effective concentration in the desired tissue. Although in some embodiments the tissue-altering molecule accumulates in non-affected tissue, this is not problematic for the individual, since precise targeting of the activating energy source to Bruch's membrane renders selective activation within the membrane. Other regions where the caged tissue-altering molecules accumulate are not treated with the activating energy; therefore, the caged tissue-altering molecules remain inactive and are eliminated via the kidneys and/or liver. In a specific embodiment, the caged molecule is not harmful or toxic in any manner and is nevertheless excreted from the body, preferably less than about 48 hours after administration, and more preferably less than about 24 hours after administration.
- the tissue-altering molecule is coupled to a specific binding ligand that may bind to a specific target molecule within Bruch's membrane.
- the target molecule may be endogenous to Bruch's membrane, or may be selectively delivered to Bruch's membrane by crosslinking the target molecule using 2- ⁇ hoton irradiation, hi these embodiments, the tissue-altering molecule will be delivered in higher concentrations to the target tissue, hi a specific embodiment, various protein-binding domains such as leucine zipper domains are associated with the tissue-altering molecule.
- the tissue-altering molecule is formulated so as to provide an effective concentration in the desired tissue. Although in some embodiments the tissue-altering molecule accumulates in non-affected tissue, this is not problematic for the individual, since precise targeting of the activation energy source to Bruch's membrane renders selective activation within this tissue. Other regions where the caged tissue-altering molecules accumulate are not treated with the activating energy; therefore, the caged tissue-altering molecules remain inactive and are eliminated via the kidneys and/or liver, hi some embodiments, the tissue-altering molecule is coupled to a specific binding ligand that may bind to a specific surface component of the target Bruch's membrane or, if desired, by formulation with a carrier that delivers higher concentrations to the target tissue. In a specific embodiment, various protein binding domains such as leucine zipper domains are associated with the tissue-altering molecule.
- the nature of the formulation will depend in part on the mode of administration and on the nature of the selected degradation molecule. Any pharmaceutically acceptable excipient, or combination thereof, appropriate to the particular tissue-altering compound may be used.
- the compound may be administered as an aqueous composition, as a topical composition, as a transmucosal or transdermal composition, in an oral formulation or intravenous formulation, in a local injection (such as periocular or intraocular) or a combination thereof.
- the formulation may also include liposomes.
- tissue-altering molecule compound can be administered in any of a wide variety of ways, for example, orally, parenterally, or rectally, or the compound may be placed directly in the eye, such as topically or by periocular injection.
- Parenteral administration such as intravenous, intramuscular, or subcutaneous, is useful.
- Intravenous, periocular, and intraocular injection are particular embodiments for delivery of the present invention or components thereof.
- the dose of tissue-altering molecule can vary widely depending on the mode of administration; the formulation in which it is carried, such as in the form of liposomes; or whether it is coupled to a target-specific ligand, such as an antibody or an immunologically active fragment.
- a target-specific ligand such as an antibody or an immunologically active fragment.
- the various parameters used for effective, selective photo-activation of the tissue-altering molecules in the invention are interrelated. Therefore, the dose should also be adjusted with respect to other parameters, for example, fluence, irradiance, duration of treatment, and time interval between administration of the dose and the therapeutic irradiation. All of these parameters should be adjusted to produce enhancement of visual function without significant damage to the ocular tissue, and a skilled artisan is well aware how to do so.
- compositions and methods related to two-photon absorption are well known in the art, although exemplary methods are described in U.S. Patent No. 6,267,913, U.S. Patent No. 6,472,541, and WO 00/31588, which are all incorporated by reference herein in their entirety.
- Proteins may be caged using a number of strategies. Caging may be accomplished by treating the native, uncaged molecule with a reactive precursor to a caging group. For example, the sidechain of the amino acid cysteine may be caged with the photo- removable o-nitrobenzyl group by treating a cysteine-containing protein with o- nitrobenzylbromide.
- Alternative strategies for caging proteins include chemical synthesis of the protein using solid-phase peptide synthesis starting with the appropriate caged amino acids, by direct translational incorporation into proteins using methods based on nonsense suppression, or by supplementing auxotrophic strains of bacteria with the caged amino acids.
- a tissue-altering molecule is caged to render it inactive, prior to localization to Bruch's membrane and activation upon exposure to an energy source.
- the tissue-altering molecule is a protein having amino acid side chains.
- a protecting group such as a photo-removable protecting groups, include cysteine, aspartate, glutamate, histidine, lysine, asparagine, glutamine, arginine, serine, threonine, or tyrosine.
- photo-removable protecting groups includes o-nitrobenzyl, desyl, phenacyl, tr ⁇ «s-o-cinnamoyl, coumarinyl, quinoline-2-only, xanthenyl, thioxanthenyl, selenoxanthenyl and anthracenyl, stilbenyl, and/or derivatives thereof. These protecting groups are added to the side chains as described elsewhere herein.
- the retina is a multilayered structure that lines the inside of the globe. It is made up of specialized cells that convert the light to electrical impulses that travel to the brain and produce sight.
- atrophic AMD The primary characteristic of atrophic AMD is accumulation of macular drusen, a localized thickening of Bruch's membrane. Diffuse thickening of Bruch's membrane (basal linear deposit) is the best histopathologic predictor of choroidal neovascularization.
- the drusen are primarily comprised of vesicular material (lipids) and cross-linked protein [0067]
- the presence of drusen is a common characteristic of macular degeneration.
- an individual having at least one eye with drusen or a thickened Bruch's membrane is treated with methods described herein.
- Caged tissue-altering enzymes are constructed by masking various amino acid sidechains within the protein using photo-removable protecting groups.
- groups are the o-nitrobenzyl, desyl, phenacyl, trar ⁇ -o-cinnamoyl, coumarinyl, quinoline-2-only, xanthenyl, thioxanthenyl, selenoxanthenyl and anthracenyl, stilbenyl and derivatives thereof.
- These groups are introduced into the proteins by total chemical synthesis (including native chemical ligation), nonsense suppression methods, or post-translational modification.
- mild detergent molecules ⁇ e.g. surfactant
- mild detergent molecules are "caged” using groups such as the o-nitrobenzyl, desyl, phenacyl, tr ⁇ ras- ⁇ -cinnamoyl, coumarinyl, quinoline-2- only, xanthenyl, thioxanthenyl, selenoxanthenyl and anthracenyl, and/or stilbenyl moieties and their derivatives thereof and likewise activated by irradiation (for example, by 2-photon irradiation) to effect selective biochemical modification of Bruch's membrane. Similar to enzyme treatment, these activated detergent molecules alter the diffusion barrier of aged Bruch's membrane to lessen the likelihood of visual loss and/or improve visual function.
- groups such as the o-nitrobenzyl, desyl, phenacyl, tr ⁇ ras- ⁇ -cinnamoyl, coumarinyl, quinoline-2- only, xantheny
- an acidic (basic) leucine zipper domain may be selectively delivered to Bruch's membrane via photo-crosslinking initiated by 2-photon irradiation.
- the enzyme is fused to a basic (acidic) leucine zipper domain and is administered, for example, systemically (such as orally or intravenously), or by injection (such as intraocular and/or periocular injection) and distributed to extracellular tissues, including Bruch's membrane. Formation of hetero-dimers within Bruch's membrane increases the local concentration of degradative enzymes and subsequently enhances trans-membrane diffusion properties. Because the concentration of these degradative enzymes will remain low in other tissues, there are no undesired collateral tissue alterations.
- the caged, inactivated molecule is fluorescent.
- the fluorescent, caged degradative complex is viewed in macular Bruch's membrane by 2 photon irradiation. After focusing on the fluorescent label in macular Bruch's membrane, a higher dose of 2 photon irradiation is applied to uncage the enzyme and initiate partial degradation of Bruch's membrane. Systemically distributed non- irradiated caged enzyme is excreted in its inactive form. Two photon irradiation viewing of labeled Bruch's membrane and photoactivation of the degradative substance are both performed at levels non-toxic to ocular structures.
- Optical coherence tomography with visible or infrared light is used to detect alterations in the physical or chemical nature of Bruch's membrane in the eye.
- OCT can be used to see not only the structure in the eye but also the mobility of the structures by Doppler OCT and the chemical nature by combining the OCT with an exogenous dye.
- the OCT and/or its variants are used to determine the nature of the Bruch's membrane with altered properties to permit guided treatment. Treatment could be the photo- uncaging or photo-activation or photo-ablation of intrinsic or extrinsic substances in or near Bruch's membrane.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003253767A AU2003253767A1 (en) | 2002-07-02 | 2003-07-01 | Treatment for eye disorder |
EP03763073A EP1539222A1 (en) | 2002-07-02 | 2003-07-01 | Treatment for eye disorder |
CA002491128A CA2491128A1 (en) | 2002-07-02 | 2003-07-01 | Treatment for eye disorder |
JP2004519718A JP2005532393A (en) | 2002-07-02 | 2003-07-01 | Treatment for eye disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39350502P | 2002-07-02 | 2002-07-02 | |
US60/393,505 | 2002-07-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004004757A1 true WO2004004757A1 (en) | 2004-01-15 |
WO2004004757A8 WO2004004757A8 (en) | 2004-10-07 |
Family
ID=30115595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/020672 WO2004004757A1 (en) | 2002-07-02 | 2003-07-01 | Treatment for eye disorder |
Country Status (6)
Country | Link |
---|---|
US (2) | US7381404B2 (en) |
EP (1) | EP1539222A1 (en) |
JP (1) | JP2005532393A (en) |
CN (1) | CN1678342A (en) |
CA (1) | CA2491128A1 (en) |
WO (1) | WO2004004757A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006075797A1 (en) * | 2005-01-14 | 2006-07-20 | Fujifilm Corporation | Tomography apparatus |
EP1755584A1 (en) * | 2004-05-07 | 2007-02-28 | The Regents Of The University Of California | Treatment of myopia |
US11300452B2 (en) | 2017-06-08 | 2022-04-12 | Ushio Denki Kabushiki Kaisha | Spectral measurement method, spectral measurement system, and broadband pulsed light source unit |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2491128A1 (en) * | 2002-07-02 | 2004-01-15 | The Regents Of The University Of California | Treatment for eye disorder |
US7654540B2 (en) * | 2004-06-18 | 2010-02-02 | Bose Corporation | Electromechanical transducing |
JP2008510529A (en) * | 2004-08-27 | 2008-04-10 | エレックス メディカル プロプライエタリー リミテッド | Selective ophthalmic laser treatment |
US7668342B2 (en) | 2005-09-09 | 2010-02-23 | Carl Zeiss Meditec, Inc. | Method of bioimage data processing for revealing more meaningful anatomic features of diseased tissues |
US7768652B2 (en) * | 2006-03-16 | 2010-08-03 | Carl Zeiss Meditec, Inc. | Methods for mapping tissue with optical coherence tomography data |
JP2009539508A (en) * | 2006-06-15 | 2009-11-19 | シーガル アイピー ピーティーワイ リミテッド | Delivery system and method |
DE102006030382A1 (en) * | 2006-06-29 | 2008-01-03 | Carl Zeiss Meditec Ag | Method and device for optical detection on the eye |
AT504159A1 (en) * | 2006-08-16 | 2008-03-15 | Marlyn Nutraceuticals Inc | USE OF PROTEASES |
US8043235B2 (en) * | 2006-08-22 | 2011-10-25 | Schwartz Donald N | Ultrasonic treatment of glaucoma |
JP2010507412A (en) | 2006-10-25 | 2010-03-11 | エレックス アールアンドディー プロプライエタリー リミテッド | Retina regeneration |
EP3305174A3 (en) * | 2007-02-15 | 2018-10-24 | The UAB Research Foundation | Improved photobleaching method |
ES2642572T3 (en) * | 2007-05-30 | 2017-11-16 | Ellex R&D Pty Ltd | Laser for rejuvenation of the retina |
EP2309919B1 (en) | 2008-07-10 | 2019-03-06 | Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO | Functional optical coherent imaging |
KR101018785B1 (en) * | 2008-11-28 | 2011-03-03 | 삼성전기주식회사 | Electromagnetic bandgap structure and circuit board |
US8609729B2 (en) * | 2009-04-15 | 2013-12-17 | Sucampo Ag | Method for treating macular degeneration |
US9226654B2 (en) | 2011-04-29 | 2016-01-05 | Carl Zeiss Meditec, Inc. | Systems and methods for automated classification of abnormalities in optical coherence tomography images of the eye |
US10575737B2 (en) | 2012-04-27 | 2020-03-03 | Novadaq Technologies ULC | Optical coherent imaging medical device |
WO2014009859A2 (en) | 2012-07-10 | 2014-01-16 | Aïmago S.A. | Perfusion assessment multi-modality optical medical device |
CN103705551A (en) * | 2013-12-02 | 2014-04-09 | 黄丽娜 | Novel GSTT (Gross Saponins of Tribulus Terrestris L) intravitreal injection drug delivery system and application thereof |
CN103656621A (en) * | 2013-12-02 | 2014-03-26 | 黄丽娜 | Novel mouse nerve growth factor intravitreal injection drug delivery system and application thereof |
CN103877430B (en) * | 2014-04-20 | 2016-04-20 | 赵华 | A kind of medicine and preparation method for the treatment of degeneration of macula |
JP6501915B2 (en) | 2015-05-07 | 2019-04-17 | ノバダック テクノロジーズ ユーエルシー | Method and system for laser speckle imaging of tissue using color image sensor |
US11273072B2 (en) | 2017-01-13 | 2022-03-15 | Gyroscope Therapeutics Limited | Suprachoroidal injection device |
AU2018218588B2 (en) * | 2017-02-09 | 2021-05-27 | Altregen Co., Ltd. | Composition comprising composite extract from ginseng/red ginseng and sea cucumber as effective ingredient for preventing or treating bruch's membrane hypofunction-related disease |
US20180360655A1 (en) * | 2017-06-16 | 2018-12-20 | Michael S. Berlin | Methods and systems for oct guided glaucoma surgery |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5310764A (en) * | 1992-05-08 | 1994-05-10 | Steven Baranowitz | Treatment of age related macular degeneration with beta-carotene |
US6059828A (en) * | 1996-03-18 | 2000-05-09 | Peyman; Gholam A. | Macular indentor for use in the treatment of subretinal neovascular membranes |
US6271233B1 (en) * | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
US20030017501A1 (en) * | 2000-02-22 | 2003-01-23 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US220245A (en) * | 1879-10-07 | Improvement in provision-safes | ||
US91229A (en) * | 1869-06-15 | Improvement in feeding-device for machines for combing- cotton | ||
US138329A (en) * | 1873-04-29 | Improvement in wheel-plows | ||
US87985A (en) * | 1869-03-16 | Improved rotary metal-cotter | ||
US6A (en) * | 1836-08-10 | Thomas blanghard | ||
US4944944A (en) * | 1987-11-19 | 1990-07-31 | Oklahoma Medical Research Foundation | Dietary compositions and methods using bile salt-activated lipase |
US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US20030087985A1 (en) | 1990-10-15 | 2003-05-08 | Hubbell Jeffrey A. | Gels for encapsulation of biological materials |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5468505A (en) | 1992-02-28 | 1995-11-21 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
JP3011768B2 (en) | 1992-02-28 | 2000-02-21 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Photopolymerizable biodegradable hydrophilic gels as tissue contacting materials and controlled release carriers |
US20040138329A1 (en) | 1992-04-20 | 2004-07-15 | Board Of Regents Of The University Of Texas System | Gels for encapsulation of biological materials |
US5800373A (en) | 1995-03-23 | 1998-09-01 | Focal, Inc. | Initiator priming for improved adherence of gels to substrates |
US5458505A (en) * | 1994-02-03 | 1995-10-17 | Prager; Jay H. | Lamp cooling system |
US5798349A (en) | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
US5935942A (en) | 1994-12-14 | 1999-08-10 | Zeimer; Ran | Selective and non-invasive visualization or treatment of vasculature |
BR9607977A (en) | 1995-03-23 | 1998-01-13 | Univ Texas | Photoinitiated and redox preparation systems for improved gel adhesion to substrates |
US6461640B1 (en) | 1995-12-08 | 2002-10-08 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
US5756541A (en) | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
CN1271277A (en) | 1997-07-18 | 2000-10-25 | 因菲米德有限公司 | Biodegradable macromers fro the controlled release of biologically active substances |
US6128525A (en) | 1997-07-29 | 2000-10-03 | Zeng; Haishan | Apparatus and method to monitor photodynamic therapy (PDT) |
CA2305349A1 (en) | 1997-10-27 | 1999-05-06 | Alexander R. Irvine | Methods and pharmaceutical compositions for the closure of retinal breaks |
US6472541B2 (en) | 1998-11-20 | 2002-10-29 | The Regents Of The University Of California | Protecting groups with increased photosensitivities |
US6858229B1 (en) | 1999-04-26 | 2005-02-22 | California Institute Of Technology | In situ forming hydrogels |
DE19920158A1 (en) * | 1999-04-29 | 2000-11-02 | Univ Schiller Jena | Method and arrangement for determining fluorophores on objects, in particular on the living fundus |
US6267954B1 (en) | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
EP1267935A2 (en) * | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Novel treatment for eye disease |
US7291673B2 (en) | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
JP2005511713A (en) | 2001-12-07 | 2005-04-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | Treatment for age-related macular degeneration |
CA2491128A1 (en) * | 2002-07-02 | 2004-01-15 | The Regents Of The University Of California | Treatment for eye disorder |
US20040199130A1 (en) * | 2003-04-03 | 2004-10-07 | Chornenky Victor I. | Apparatus and method for treatment of macular degeneration |
-
2003
- 2003-07-01 CA CA002491128A patent/CA2491128A1/en not_active Abandoned
- 2003-07-01 JP JP2004519718A patent/JP2005532393A/en active Pending
- 2003-07-01 EP EP03763073A patent/EP1539222A1/en not_active Withdrawn
- 2003-07-01 US US10/611,013 patent/US7381404B2/en not_active Expired - Fee Related
- 2003-07-01 WO PCT/US2003/020672 patent/WO2004004757A1/en active Application Filing
- 2003-07-01 CN CNA038208113A patent/CN1678342A/en active Pending
-
2008
- 2008-05-23 US US12/126,100 patent/US8298521B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5310764A (en) * | 1992-05-08 | 1994-05-10 | Steven Baranowitz | Treatment of age related macular degeneration with beta-carotene |
US6059828A (en) * | 1996-03-18 | 2000-05-09 | Peyman; Gholam A. | Macular indentor for use in the treatment of subretinal neovascular membranes |
US6271233B1 (en) * | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
US20030017501A1 (en) * | 2000-02-22 | 2003-01-23 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1755584A1 (en) * | 2004-05-07 | 2007-02-28 | The Regents Of The University Of California | Treatment of myopia |
EP1755584A4 (en) * | 2004-05-07 | 2007-10-31 | Univ California | Treatment of myopia |
US7727544B2 (en) | 2004-05-07 | 2010-06-01 | The Regents Of The University Of California | Treatment of myopia |
WO2006075797A1 (en) * | 2005-01-14 | 2006-07-20 | Fujifilm Corporation | Tomography apparatus |
US11300452B2 (en) | 2017-06-08 | 2022-04-12 | Ushio Denki Kabushiki Kaisha | Spectral measurement method, spectral measurement system, and broadband pulsed light source unit |
Also Published As
Publication number | Publication date |
---|---|
EP1539222A1 (en) | 2005-06-15 |
US20080286255A1 (en) | 2008-11-20 |
CA2491128A1 (en) | 2004-01-15 |
WO2004004757A8 (en) | 2004-10-07 |
CN1678342A (en) | 2005-10-05 |
JP2005532393A (en) | 2005-10-27 |
US20050048044A1 (en) | 2005-03-03 |
US7381404B2 (en) | 2008-06-03 |
US8298521B2 (en) | 2012-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8298521B2 (en) | Treatment for eye disorder | |
US20030171320A1 (en) | Methods for treating ocular neovascular diseases | |
US6984655B1 (en) | Photodynamic therapy for selectively closing neovasa in eyeground tissue | |
Neelam et al. | Choroidal neovascularization in pathological myopia | |
AU2002230567B2 (en) | Compositions for treatment of ocular neovascularization and neural injury | |
CZ278998A3 (en) | Method of improving eyesight by making use of photodynamic therapy of eye | |
JP2007536272A (en) | Myopia treatment | |
Costa et al. | Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy | |
RU2286157C2 (en) | Means for introducing into vitreous body for treating or preventing ophthalmic diseases | |
Reibaldi et al. | Low-fluence photodynamic therapy in longstanding chronic central serous chorioretinopathy with foveal and gravitational atrophy | |
Rechtman et al. | An update on photodynamic therapy in age-related macular degeneration | |
Tarantola et al. | Photodynamic therapy as treatment of chronic idiopathic central serous chorioretinopathy | |
Spaide | Central serous chorioretinopathy | |
Moshfeghi et al. | Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies | |
AU2003253767A1 (en) | Treatment for eye disorder | |
RU2682496C1 (en) | Method of laser treatment of chronic recurrent central serous chorioretinopathy | |
Singh et al. | The use of dye in ophthalmology | |
KR20050021375A (en) | Treatment for eye disorder | |
Bouzika et al. | Peripapillary pachychoroid syndrome (PPS): Diagnosing and treating a rare entity | |
WO2006107598A2 (en) | Conjugates of photoactive compound and a bulking group for enhancing photodynamic therapy | |
JP2008507588A (en) | Methods of treating eye conditions | |
Gohto et al. | Accumulation of photosensitizer ATX-S10 (Na) in experimental corneal neovascularization | |
JP2004530645A (en) | Methods for treating specific eye diseases | |
Serebryakov et al. | Alternative approach to laser methods of treating vascular pathologies of the eye | |
Karacorlu et al. | Photodynamic therapy with delayed light application for the treatment of bilateral subfoveal choroidal neovascularization in age-related macular degeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 03/2004 UNDER (22) REPLACE "07 JULY 2003 (07.07.03)" BY "01 JULY 2003 (01.07.03)" |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003253767 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004519718 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2491128 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047021664 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003763073 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038208113 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047021664 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003763073 Country of ref document: EP |